Mattawan, Mich. – MPI Research affirmed its position as a global leader in pathology capabilities today, announcing the addition of industry experts Justin Vidal, DVM, PhD, DACVP, and Joshua Decker, DVM, DACVP.
Dr. Vidal, internationally recognized as one of the world’s leading experts within the reproductive toxicologic pathology field, joins MPI Research as Senior Principal Pathologist.
“The addition of a truly elite talent such as Dr. Vidal to our team creates important new opportunities for MPI Research and our Sponsors,” said Dr. Daniel Patrick, Director of Pathology. “His specialization in reproductive studies encompasses a growing area of concern and interest for pharmaceutical and chemical developers worldwide.”
In addition to expanding the company’s pathology capabilities, Dr. Vidal’s skills will enhance the already expansive services offered through the Developmental and Reproductive Toxicology (DART) team. He has more than 15 years of specialized experience, including eleven years at GlaxoSmithKline as Director and Head of Pathology, and most recently serving as Senior Pathologist with Vet Path Services, Inc., where he provided pathology support for numerous biopharmaceutical companies and consulted on reproductive toxicologic pathology and drug development. Dr. Vidal will continue to provide reproductive consultative services in his full-time position at MPI Research.
Dr. Decker joins MPI Research as Senior Principal Pathologist, providing high quality pathology support for drug and device sponsors across a wide variety of species and compound classes. Of his more than ten years of toxicologic pathology experience, Dr. Decker spent the last eight at Abbvie Inc., as Principal Pathologist in Preclinical Safety, interpreting pathology findings in toxicology studies of pharmaceutical compounds.
Dr. Decker’s considerable experience includes working with a wide range of animal models, performing pathology peer reviews, consulting on projects characterizing cardiovascular and skeletal muscle toxicity, and providing pathology support for Discovery and Comparative Medicine.
“The addition of both of these exceptional and uniquely accomplished individuals to our pathology team is part of our strategic commitment to successfully accommodate current market demands and build for the future,” said Patrick.
As the largest single-site preclinical CRO in the world, MPI Research has the distinguishing advantage of strong interdepartmental collaboration. Recent investments in pathology personnel and infrastructure have fostered unique opportunities for the establishment of sound partnerships yielding enhanced specialty capabilities such as those now available within ophthalmology and auditory safety research.